RBC Capital on Intercept Pharma (ICPT): Benign Label Update Removes Key Overhang, Should Set Stage for Ocaliva Growth
February 1, 2018 9:42 AM
RBC Capital maintains Outperform on Intercept Pharmaceuticals (NASDAQ: ICPT).Analyst Brian Abrahams comments "FDA has just updated Ocaliva's label with what ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
